AEterna Zentaris Breakout on FDA Catalysts
The Market Financial Breaking News Newsletter
If you are having trouble viewing this message, please go to http://community.icontact.com/p/stockshaven/newsletters/distributionlistpublic/posts/aeterna-zentaris-breakout-on-fda-catalysts [1][2] Breaking News and Insider Scoops April 21, 2011 AEterna Zentaris Placed On Breakout Alert Ahead of FDA Catalysts (NASDAQ:AEZS) AEterna Zentaris has three critical FDA catalysts coming up in the 2nd half of the year which could propel it to new highs:
1) Perifosine (KRX-0401) Pivotal Phase 3 study completion and top-line results, an inhibitor anti-cancer agent for relapsed / refractory multiple myeloma.
2) SOLOREL, treatment of maci-morelin (AEZS-130), announced SPA agreement and expects results during 1st half 2011 to support NDA filing by end of year.
3) AEZS-108, a LHRH agonist linked doxorubicin conjugate, for endometrial cancer, expects to begin phase 3 pivotal study in mid 2011.
Technical Analysis:
http://chart.ly/uploads/large_8wgyu72.png1303395241 Full chart: [3]http://chart.ly/uploads/large_8wgyu72.png1303395241 We will have a report coming out this weekend on potential target market, price target, financial conditions and more.
Latest Updates ___________________________________________________________________________ * $AEZS looks to breakout to new 52-week highs * $AVNR partnership may be close, expect stellar earnings report [4] [5]Disclaimer | [6]Terms of Use | [7]Contact Us | [8]About Us | [9]Become an Author |
Related posts:
- Oxigene Nears Cancer FDA Catalysts
- Oxigene ASCO Meeting in June
- A Perfect Time To Buy FDA Play, AEZS
- High Trade Alert On AEZS